In HER2+ breast tumors, PIK3CA mutation (H1047R, E545K, or both) was found in 63% of tumors, which may subvert the efficacy of HER2-targeted therapies and ultimately result in relapse. This evidence concerns the gene ERBB2 and breast neoplasm.